
    
      This is a multicenter, prospective, open label, self-controlled, single group study of the
      efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and
      best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast
      5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days
    
  